The Prognostic Significance Of Pretreatment Albumin/alkaline Phosphatase Ratio In Patients With Stage IB-IIA Cervical Cancer. 2019

Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
Department of Gynecology Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, People's Republic of China.

BACKGROUND Pretreatment albumin/alkaline phosphatase ratio (AAPR) has been discussed about its prognostic value in several malignancies, whereas its role in cervical cancer remains unclear. In this study, we attempt to explore the prognostic significance of the AAPR in stage IB-IIA cervical cancer patients who underwent a radical hysterectomy. METHODS A total of 230 cervical cancer patients were enrolled in this retrospective study. The threshold value of AAPR was determined by receiver operating characteristic (ROC) curve. Kaplan-Meier survival analysis and multivariate analysis were performed to identify independent prognostic predictors of disease-free survival (DFS) and overall survival (OS). RESULTS The optimal cut-off value of the preoperative AAPR was 0.68. Patients with AAPR<0.68 showed obviously inferior OS and DFS than those with AAPR>0.68 according to Kaplan-Meier curves (DFS: P = 0.011; OS: P = 0.017). In multivariate analysis, the preoperative AAPR showed to be an independent predictive factor for disease-free survival (DFS: P = 0.015) and overall survival (OS: P = 0.019). Moreover, subgroup analysis revealed that the lower AAPR was correlated with worse prognosis in patients with histologic grade I-II; but in those with histologic grade III, there was no significant difference between the two groups. CONCLUSIONS Preoperative AAPR was a potentially valuable prognostic index in stage IB-IIA cervical cancer patients. Further prospective studies are required to validate its prognostic value.

UI MeSH Term Description Entries

Related Publications

Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
January 2018, Cancer medicine,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
July 2020, BMC cancer,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
January 2023, PloS one,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
January 2021, Pathology oncology research : POR,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
January 2019, Cancer management and research,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
January 2020, BioMed research international,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
February 2006, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
June 1993, Gynecologic oncology,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
September 2022, Clinical and experimental nephrology,
Can Zhang, and Yong Li, and Rui Ji, and Weiling Zhang, and Chenfei Zhang, and Youli Dan, and Hongyan Qian, and Aiqin He
June 2016, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Copied contents to your clipboard!